Pazzucconi F, Mannucci L, Mussoni L, Gianfranceschi G, Maderna P, Werba P, Franceschini G, Sirtori C R, Tremoli E
E. Grossi Paoletti Center, Institute of Pharmacological Sciences, University of Milan, Italy.
Eur J Clin Pharmacol. 1992;43(3):219-23. doi: 10.1007/BF02333013.
The effects of bezafibrate 400 mg/day (slow release formulation) on plasma lipids/lipoproteins and on selected haemostatic parameters were evaluated in a double blind cross-over study in patients with Type IIb and IV hyperlipoproteinaemia. Placebo treatment did not influence any of those parameters, but the drug significantly reduced plasma triglycerides (-45%) and VLDL cholesterol, as well as causing a 12% fall in total cholesterol and a 20% increase in HDL cholesterol. Apo AI levels were significantly increased following bezafibrate and Apo B was reduced by about 20%. In addition to changes in the plasma lipid profile, bezafibrate reduced the sensitivity of platelets to the aggregatory effect of collagen, with no effect on TXB2 production. Fibrinogen levels after bezafibrate treatment were significantly lowered, the effect being more marked in patients with hyperfibrinogenaemia. Bezafibrate did not influence the plasma fibrinolytic profile. It is concluded that bezafibrate, besides its beneficial effects on the plasma lipoprotein profile, can exert beneficial changes on specific haemostatic parameters.
在一项针对IIb型和IV型高脂蛋白血症患者的双盲交叉研究中，评估了每天400毫克（缓释制剂）苯扎贝特对血浆脂质/脂蛋白以及选定止血参数的影响。安慰剂治疗对这些参数均无影响，但该药物显著降低了血浆甘油三酯（-45%）和极低密度脂蛋白胆固醇，同时使总胆固醇下降了12%，高密度脂蛋白胆固醇增加了20%。服用苯扎贝特后，载脂蛋白AI水平显著升高，载脂蛋白B降低了约20%。除了血浆脂质谱的变化外，苯扎贝特降低了血小板对胶原蛋白聚集作用的敏感性，对血栓素B2的产生没有影响。苯扎贝特治疗后的纤维蛋白原水平显著降低，在纤维蛋白原血症患者中效果更明显。苯扎贝特不影响血浆纤维蛋白溶解谱。得出的结论是，苯扎贝特除了对血浆脂蛋白谱有有益作用外，还可对特定止血参数产生有益变化。
